Daniel Spakowicz, PhD – The James – Ohio State University Comprehensive Cancer Center discusses Microbiome Might Reveal Whether Immune Therapy…
Browsing: Immunotherapy
Jason Luke, MD, FACP, is an associate professor of medicine in the Division of Hematology/Oncology at the University of Pittsburgh…
Jason Luke, MD, FACP, is an associate professor of medicine in the Division of Hematology/Oncology at the University of Pittsburgh…
Jason Luke, MD, FACP, is an associate professor of medicine in the Division of Hematology/Oncology at the University of Pittsburgh…
Jason Luke, MD, FACP, is an associate professor of medicine in the Division of Hematology/Oncology at the University of Pittsburgh…
Juan Carlos Varela, MD AdventHealth discusses AdventHealth launches first-of-its-kind immunotherapy treatment, clinical trial for specific blood cancer patients.
Juan Carlos Varela, MD – AdventHealth discusses AdventHealth launches first-of-its-kind immunotherapy treatment, clinical trial for specific blood cancer patients
Juan Carlos Varela, MD AdventHealth discusses AdventHealth launches first-of-its-kind immunotherapy treatment, clinical trial for specific blood cancer patients.
Nicolas Poirier, Ph.D. – OSE Immunotherapeutics – discusses Identifies Monoclonal Antibody Antagonists of CLEC-1 as New Checkpoint Inhibitors of Immune…
Nicolas Poirier, Ph.D. – OSE Immunotherapeutics – discusses – Identifies Monoclonal Antibody Antagonists of CLEC-1 as New Checkpoint Inhibitors of…
William Dale, MD @WilliamDale_MD of City of Hope @CityofHope discusses integrated geriatric assessment and treatment (INTEGERATE) in older people with…
William Dale, MD @WilliamDale_MD of City of Hope @CityofHope discusses integrated geriatric assessment and treatment (INTEGERATE) in older people with…
William Dale, MD @WilliamDale_MD of City of Hope @CityofHope discusses integrated geriatric assessment and treatment (INTEGERATE) in older people with…
Daneng Li, MD @DanengLi of City of Hope @cityofhope on geriatric assessment-driven intervention (GAIN) on chemotherapy toxicity in older adults…
Daneng Li, MD @DanengLi of City of Hope @cityofhope on geriatric assessment-driven intervention (GAIN) on chemotherapy toxicity in older adults…
Robert Epstein, MD, MS of Epstein Health LLC on real-world burden of chemotherapy-induced myelosuppression: results of a U.S. online survey…
Robert Epstein, MD, MS of Epstein Health LLC on real-world burden of chemotherapy-induced myelosuppression: results of a U.S. online survey…
Robert Epstein, MD, MS of Epstein Health LLC on real-world burden of chemotherapy-induced myelosuppression: results of a U.S. online survey…
Heather Losey, PhD of Alkermes discusses ALKS 4230: a novel engineered IL-2 fusion protein with an improved cellular selectivity profile…
Dominik Mumberg, PhD of Bayer @Bayer @BayerPharma discusses the investigational small molecule aryl hydrocarbon receptor (AhR) inhibitor BAY 2416964 to…
Dominik Mumberg, PhD of Bayer @Bayer @BayerPharma discusses the investigational small molecule aryl hydrocarbon receptor (AhR) inhibitor BAY 2416964 to…
Dominik Mumberg, PhD of Bayer @Bayer @BayerPharma discusses the investigational small molecule aryl hydrocarbon receptor (AhR) inhibitor BAY 2416964 to…
David Hong, MD of MD Anderson Cancer Center @MDAndersonNews discusses at this year’s virtual AACR the efficacy and safety of…
David Hong, MD of MD Anderson Cancer Center @MDAndersonNews discusses at this year’s virtual AACR the efficacy and safety of…
David Hong, MD of MD Anderson Cancer Center @MDAndersonNews discusses at this year’s virtual AACR the efficacy and safety of…
Ecaterina Dumbrava, MD of MD Anderson Cancer Center @MDAndersonNews discusses the phase I trial of COM701 presented at the virtual…
Ecaterina Dumbrava, MD of MD Anderson Cancer Center @MDAndersonNews discusses the phase I trial of COM701 presented at the virtual…
Ecaterina Dumbrava, MD of MD Anderson Cancer Center @MDAndersonNews discusses the phase I trial of COM701 presented at the virtual…
Brenda De Keersmaecker of eTheRNA Immunotherapies discusses a strong link between T cell activation and durable clinical benefit (DCB) in…
Brenda De Keersmaecker of eTheRNA Immunotherapies discusses a strong link between T cell activation and durable clinical benefit (DCB) in…
Brenda De Keersmaecker of eTheRNA Immunotherapies discusses a strong link between T cell activation and durable clinical benefit (DCB) in…
Paulo Rodriguez, PhD of Moffitt Cancer Center @MoffittNews explains immunosuppression in tumors overall in the study. ______________ An active immune…
Paulo Rodriguez, PhD of Moffitt Cancer Center @MoffittNews answers what the effects are in activation for identifying molecular pathways that…
Paulo Rodriguez, PhD of Moffitt Cancer Center @MoffittNews discusses identifying molecular pathways that control immunosuppression in tumors. ______________ An active…
Tom Davis, MD @ThomasADavisMD of @GenoceaBio answers the advancing part B of GEN-009 phase 1/2a trial with first patient dosed…
Tom Davis, MD @ThomasADavisMD of @GenoceaBio answers the advancing part B of GEN-009 phase 1/2a trial with first patient dosed…
Tom Davis, MD @ThomasADavisMD of @GenoceaBio discusses the advancing part B of GEN-009 phase 1/2a trial with first patient dosed…
 Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and leader in predictive target discovery, today announced its plan to initiate a Phase…
Adult cancer patients reported better physical and social function after undergoing CAR-T therapy Adult lymphoma patients whose disease was effectively…
Joseph Alvarnas, MD @cityofhope Vice President of Government Affairs, Senior Medical Director for Employer Strategy, Director of Value Based Analytics,…
Joseph Alvarnas, MD @cityofhope Vice President of Government Affairs, Senior Medical Director for Employer Strategy, Director of Value Based Analytics,…
Joseph Alvarnas, MD @cityofhope Vice President of Government Affairs, Senior Medical Director for Employer Strategy, Director of Value Based Analytics,…
GRACE is excited to bring to our Spanish speaking community information on Cancer Basics.Our friend and partner, Narjust (N.J.) Duma,…
Betty Hamilton, MD of @ClevelandClinic discusses the post-transplant work statue of young adult survivors of allogeneic hematopoietic cell transplant.
Jay Andersen, MD of Compass Oncology discusses the phase 3 KEYNOTE-522 trial was investigating KEYTRUDA (pembrolizumab), Merck’s anti-PD-1 immunotherapy, in…
Chadi Nabhan, MD MBA of Aptitude Health discusses potential of biosimilars in treatment of blood cancer.
Shyamala Navada, MD of @MountSinaiNYC discusses the phase II study of oral rigosertib combined with azacitidine as first line therapy…
Robert Rifkin, MD of @TheUSONetwork discusses the Lyra study.
Jan Hillson, MD of @AlpineImmuneSci disucsses ALPN-101.
Duvelisib Achieves Overall Response Rate of 62% in Patients with Relapsed or Refractory PTCL with Manageable Safety Profile in Initial…